JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target Astria is using its half-life extension technology to develop long-acting mAbs targeting “de-risked targets in large, proven markets,” the analyst tells investors in a research note. The firm says the company’s lead candidate, navenibart, which is starting Phase 3 testing to prevent hereditary angioedema attacks, is addressing a “proven, blockbuster market.” JMP says navenibart has a de-risked mechanism with extended durability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria initiates Phase 1a Trial of STAR-0310 trial, sees proof of concept in Q3
- Astria Therapeutics designs ALPHA-ORBIT Phase 3 trial of navenibart in HAE
- Astria Therapeutics Unveils Phase 3 Trial for Navenibart
- Astria Therapeutics Expands Stock Incentive Plan
- Astria Therapeutics price target raised to $32 from $28 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com